HR Execs on the Move

Enterin Inc.

www.enterininc.com

 
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Essen Health Care

essen Health Care is a healthcare continuum in New York with over 300 providers across Manhattan, Bronx, Queens, Staten Island, Long Island and Westchester County. Essen is a patient focused integrated healthcare delivery platform with the goal of prov...

Kiosk Group Inc

Kiosk Group Inc is a Knoxville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EKOS Corporation

EKOS Corporation was founded in 1995 with the vision that ultrasound could accelerate the delivery of drugs to benefit patients with a variety of diseases and conditions. Today, EKOS is the world leader in providing ultrasound-assisted, fluid infusion

Allergen Research

Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.

Indiana Perinatal Network Inc

Indiana Perinatal Network Inc is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.